BBB | Healthcare & Research

Change towards innovation

Cancer caused 43.8 million illness throughout the world and had burdened USD 1.16 trillion according to 2018 World Cancer Report, published by International Agency for Research on Cancer (IARC) of WHO. The prevalence rate is estimated to spike when people who have a cancer but not being diagnosed are included. Cancer has been prevalent nowadays and yet the disease still comes with fear and anxiety. To fight against cancer and get back to daily lives, “Quality healthcare service” is essential. But what if your’re not within the reach of skilled healthcare providers, up-to-date medical equipment and adequate medical insurance fund? The results speak for themselves.

BBB wanted to make a breakthrough. As a healthcare technology startup, we set a clear goal of launching a blood testing product which does not require high-end infrastructure to offer “Quality healthcare service.” Keeping this well-defined yet challenging ambition in mind, BBB took the first step towards developing MARK-B. MARK-B should be more of a good testing product. A quality blood tester is all about “accuracy”. MARK-B™ reads blood proteins in an “easy, quick and accurate” manner. EASY, QUICK and ACCURATE ― these three keywords are feasible thanks to unique electrochemical immunoassay method. The sophisticated method presents accuracy equivalent to lab quality in a handy device, by selecting proteins with antibodies and analyzing electrochemical signal to draw quantitative results. Accurate content of a certain protein not only allows detecting early stage cancer but also monitoring patients under treatment. Presenting lab quality service outside the lab ― the innovative experience for both healthcare professionals and patients.

Another key technology behind MARK-B™’s accurate diagnosis is non-powered automatic plasma separation. The tester automatically segregates pure (100%) plasma from traces of whole blood less than a single minute. It doesn’t need centrifugation before the test, optical elements or devices. That’s how BBB succeed in making more reliable and durable blood tester, MARK-B™. BBB’s challenge is to pave the way for novel healthcare services through innovative technology. Change towards innovationᅳ that’s the core value of MARK B™ and BBB. - BBB inc. CEO& Founder Jaekyu Choi

Our History

2020. 06 BBB-Celltrion, succeed on joint development of COVID-19 diagnostic kit

2020. 06 'MARK-B™ COVID-19 Ag S' test cartridge CE certification

2020. 01 'MARK-B™ analyzer' CE certification, 'MARK-B™ CEA' test cartridge CE certification

2019. 03 Completed a Joint “Cancer Diagnostic Performance Verification Clinical Trial” with Seoul National University Bundang Hospital

2018. 10 Raised 16.5 million in 'Series B'

2018. 07 Presented MARK-B™ Technology at AACC(American Association for Clinical Chemistry) in Chicago, USA

2018. 03 ‘MARK-B™ cancer’ Clinical testing and joint research with Seoul National University Bundang Hospital

2017. 11 Launched elemark® dual check in Korea

2017. 08 Signed OEM contract with GenBody Inc. for supply of rapid test readers for arboviruses and drugs of abuse

2017. 06 Signed MOU with Korea University Guro Hospital to develop next-generation immunodiagnostic kit for cancer, myocardial infarction, and chronic disease

2017. 06 Signed MOU with Busan University to commercialize medical research and infrastructure

2017. 04 Signed OEM contract with Philosys Inc. for supply of glucosmeters for hospital use

2016. 08 Raised $5 million in 'Series A' round

2015. 10 Winner of Zhongguancun Innoway <2015 Demo The World> in Smart Hardware Sector

2015. 05 Tech-In-Asia Award Winner <beGlobal Seoul 2015>

2015. 04 Signed OEM contract with GreenCross MS for supply of in-vitro diagnostic devices for hospitals

2015. 01 Joined HAX Batch 6 program

2014. 10 Founded headquarters in Korea

Products

elemark®

neurogear™

MARK-B™

Resent Publications

Clinical Laboratory

August, 2019

“Evaluation of MARK-B for Quantitative Measurement of Three Tumor Markers:

Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen”

Tumor marker assays have played a crucial role for screening cancers and monitoring cancer patients, as they reflect the status and prognosis of patients. Alpha fetoprotein (AFP), prostate specific antigen (PSA), and carcinoembryonic antigen (CEA) are the most commonly used tumor marker proteins. The MARK B™ immunoassay system is a novel platform based on magnetic nanoparticles and electrochemical immunoassay. read

Analytica Chimica Acta

March, 2019

“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays

for quantification of prostate-specific antigen in human serum”

We propose a new immunoassay technique, called magnetic-force assisted electrochemical sandwich immunoassay (MESIA), where serum biomarkers can be determined by magnetic actuation and electrochemical detection of gold-coated iron oxide nanoparticles as probes for immunocomplex formation. In MESIA, neither washing buffer nor fluidic parts are necessary, because the formation of immunocomplexes and the removal of unbound probes are controlled by magnetic forces. read

Biosensors and Bioelectronics

July, 2018

“Magnetic force assisted electrochemical sensor for the detection of thrombin

with aptamer-antibody sandwich formation”

A magnetic force assisted electrochemical aptamer-antibody sandwich assay(MESA) was developed for the detection of thrombin as a model protein in serum samples. The MESA using the formation of sandwich complexes on the electrochemical sensor probe for reaction and the removal of unbound bioconjugates from the sensor surface without washing are controlled by a magnetic field. read

Download BBB Company brief 2019

Corporate Information

DAECHI CENTER - BUSINESS OFFICE

14F, 26, Samseong-ro 85-gil, Gangnam-gu, Seoul, Republic of Korea

+82-2-565-9653

biz@bbbtech.com [Sales Team]

contact@bbbtech.com [Any other Question]

YATAP CENTER - MAIN OFFICE

28, Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea